OGM for Hematological Malignancies
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) and other blood cancers
Clinical ResearchValidation Studies
Key Facts
Indication
Myelodysplastic Syndromes (MDS), Acute Myeloid Leukemia (AML) and other blood cancers
Phase
Clinical Research
Status
Validation Studies
Company
About Bionano Genomics
Bionano Genomics is on a mission to transform the way the world sees the genome through its optical genome mapping technology, which detects structural variants missed by traditional cytogenetics and sequencing. The company has commercialized its OGM systems and software, with over 500 publications citing its use in research and clinical applications. Bionano's strategic focus is on driving adoption in clinical cytogenomics and research labs to improve the diagnosis and understanding of cancers and genetic diseases.
View full company profile